Large, randomized trial shows integrative approach relieves common side effect of estrogen-suppressing drug
Dec. 7, 2017
| By Diane Mapes / Fred Hutch News Service
Results from a large multicenter trial released Thursday at the San Antonio Breast Cancer Symposium offer good news to early stage breast cancer patients dealing with painful side effects from powerful estrogen-squelching drugs known as aromatase inhibitors.
Li study confirms his earlier finding that associates long-term tamoxifen use with more than four-fold increased risk of aggressive, difficult to treat type of contralateral breast cancer
Aug. 26, 2009
| By Kristen Woodward
Findings by Dr. Christopher Li, and colleagues at the Fred Hutchinson Cancer Research Center indicate that while long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.
Linden and colleagues find PET scans can provide accurate, early assessment of response to breast-cancer therapy
June 1, 2009
| By Dean Forbes
Dr. Hannah Linden of the Seattle Cancer Care Alliance and colleagues discovered the response of patient's with estrogen receptor positive breast cancer to standard aromatase-inhibitor therapy can be measured by noninvasive imaging with similar results to invasive needle sampling.